Stay updated with breaking news from Priya Singhal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON, MA / ACCESSWIRE / May 23, 2024 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of discussion and networking at its annual Longwood
:max_bytes(150000):strip_icc()/GettyImages-1742678123-27c9d18e27274ea7a0a3ff747178c5bb.jpg)
Biogen has agreed to pay at least $1.15 billion for biotech firm Human Immunology Biosciences as it moves to increase its immunology portfolio.
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational
HI-Bio is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications.